[{"id":"247549cd-8895-4562-99d4-e47d7bf8dd69","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923104","created_at":"2021-01-18T03:34:22.610Z","updated_at":"2025-02-25T13:48:00.941Z","phase":"","brief_title":"An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin","source_id_and_acronym":"NCT00923104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL1B • MMP1","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B • MMP1"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 04/23/2009","start_date":" 04/23/2009","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"8558f5f4-3c34-4ca5-977c-ce483a267ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06811220","created_at":"2025-02-25T16:50:25.446Z","updated_at":"2025-02-25T16:50:25.446Z","phase":"Phase 3","brief_title":"The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients","source_id_and_acronym":"NCT06811220","lead_sponsor":"Alexandria University","biomarkers":" TNFA • IL1B","pipe":"","alterations":" ","tags":["TNFA • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/27/2025","start_date":" 01/27/2025","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-06"},{"id":"c18480ea-e56b-4074-80ac-afaf290dce63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556045","created_at":"2021-01-18T21:46:44.852Z","updated_at":"2025-02-25T16:53:16.785Z","phase":"","brief_title":"Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer","source_id_and_acronym":"NCT04556045","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-04"},{"id":"2e87885c-4e7c-4eee-af7f-c60a1af4ea15","acronym":"SPIRAL","url":"https://clinicaltrials.gov/study/NCT06785974","created_at":"2025-02-25T19:12:33.814Z","updated_at":"2025-02-25T19:12:33.814Z","phase":"Phase 4","brief_title":"Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis","source_id_and_acronym":"NCT06785974 - SPIRAL","lead_sponsor":"Erasmus Medical Center","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-01-22"},{"id":"a062c74c-382b-45ce-ae14-0fed8ad9e6f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06666881","created_at":"2025-02-26T15:17:28.737Z","updated_at":"2025-02-26T15:17:28.737Z","phase":"","brief_title":"Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients","source_id_and_acronym":"NCT06666881","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-10-31"},{"id":"818fa4a2-3999-4978-a908-8798a8ccd16f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06664736","created_at":"2025-02-26T15:16:43.450Z","updated_at":"2025-02-26T15:16:43.450Z","phase":"","brief_title":"Effects of Home-Based Exercise Program in Children After Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06664736","lead_sponsor":"Gazi University","biomarkers":" IL6 • TNFA • IL1B • BDNF","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B • BDNF"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2024-10-29"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"fab7c1a5-865b-44d1-9464-2b668a7a8d95","acronym":"","url":"https://clinicaltrials.gov/study/NCT06626633","created_at":"2025-02-26T15:02:37.996Z","updated_at":"2025-02-26T15:02:37.996Z","phase":"Phase 1","brief_title":"2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML","source_id_and_acronym":"NCT06626633","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-10-04"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"00fbcb73-e5c3-4e5c-acd5-7c34ad0c92f2","acronym":"RBSNAAMCL","url":"https://clinicaltrials.gov/study/NCT06469047","created_at":"2025-02-26T14:17:30.489Z","updated_at":"2025-02-26T14:17:30.489Z","phase":"","brief_title":"Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia","source_id_and_acronym":"NCT06469047 - RBSNAAMCL","lead_sponsor":"Second Hospital of Shanxi Medical University","biomarkers":" IL1B","pipe":"","alterations":" ","tags":["IL1B"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-21"},{"id":"1e9b7c00-43dd-4165-b7a2-f9e69ef6622c","acronym":"YES","url":"https://clinicaltrials.gov/study/NCT04906200","created_at":"2024-06-15T04:15:02.239Z","updated_at":"2024-07-02T16:34:27.679Z","phase":"","brief_title":"Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors","source_id_and_acronym":"NCT04906200 - YES","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" IL6 • IL10 • IL1B","pipe":"","alterations":" ","tags":["IL6 • IL10 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/28/2021","start_date":" 06/28/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-06-10"},{"id":"c1b27e69-5cb6-4c7f-a2c7-df42fb2ed239","acronym":"CYTOK-AZA","url":"https://clinicaltrials.gov/study/NCT06439199","created_at":"2024-06-08T04:34:20.475Z","updated_at":"2024-07-02T16:34:59.405Z","phase":"","brief_title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","source_id_and_acronym":"NCT06439199 - CYTOK-AZA","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/15/2024","start_date":" 06/15/2024","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-03"},{"id":"b59bb53b-410d-4acf-9867-d978938a0bfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04400071","created_at":"2021-01-18T21:13:43.825Z","updated_at":"2024-07-02T16:34:59.833Z","phase":"","brief_title":"Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment","source_id_and_acronym":"NCT04400071","lead_sponsor":"Indiana University","biomarkers":" IFNG • IL6 • TNFA • IL10 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 08/07/2020","start_date":" 08/07/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-31"},{"id":"6d0b40ae-0057-41ed-9ea5-d6965f8e7aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238027","created_at":"2021-01-18T16:00:03.519Z","updated_at":"2024-07-02T16:35:03.052Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03238027","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • PD-L2 • IL2 • IL10 • CSF1R • IL1B • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Niktimvo (axatilimab-csfr)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2024-05-17"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"853b2c7a-ae04-4c10-89b6-0e2751505bec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04812652","created_at":"2024-05-04T04:26:52.545Z","updated_at":"2024-07-02T16:35:06.634Z","phase":"","brief_title":"Digitally Distributed Yoga for Women Treated for Breast Cancer","source_id_and_acronym":"NCT04812652","lead_sponsor":"Region Örebro County","biomarkers":" TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 229","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-01"},{"id":"0a0424c7-9b19-4e63-af51-633e80f32ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02782949","created_at":"2021-01-18T13:39:03.685Z","updated_at":"2024-07-02T16:35:06.989Z","phase":"Phase 2","brief_title":"Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia","source_id_and_acronym":"NCT02782949","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • CXCL8 • IL1B","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IL1B"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/04/2017","start_date":" 04/04/2017","primary_txt":" Primary completion: 10/06/2022","primary_completion_date":" 10/06/2022","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-30"},{"id":"d69e14be-12ab-4d05-911e-0e6d60227602","acronym":"CATCH","url":"https://clinicaltrials.gov/study/NCT04188912","created_at":"2021-01-18T20:25:07.418Z","updated_at":"2024-07-02T16:35:09.852Z","phase":"","brief_title":"Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study","source_id_and_acronym":"NCT04188912 - CATCH","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IFNG • IL6 • IL2 • IL10 • FOXP3 • IL17A • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • IL2 • IL10 • FOXP3 • IL17A • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-04-12"},{"id":"d8ba5db8-31ec-4bba-b3c0-09c4fe1069df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04391543","created_at":"2021-01-18T21:11:38.892Z","updated_at":"2024-07-02T16:35:10.769Z","phase":"","brief_title":"BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory)","source_id_and_acronym":"NCT04391543","lead_sponsor":"Le Mans Universite","biomarkers":" IL6 • TNFA • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 08/15/2023","primary_completion_date":" 08/15/2023","study_txt":" Completion: 02/15/2025","study_completion_date":" 02/15/2025","last_update_posted":"2024-04-09"},{"id":"a01dd9f5-a287-4b7c-81c3-e982628b8af0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06199947","created_at":"2024-01-11T22:20:15.626Z","updated_at":"2024-07-02T16:35:23.958Z","phase":"","brief_title":"Study of the Role of Oncostatin M in Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06199947","lead_sponsor":"Poitiers University Hospital","biomarkers":" IL6 • TNFA • IL10 • IL17A • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • IL1B"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-10"},{"id":"c684a821-6f24-49f9-8bae-75d401eba5f5","acronym":"M-Tech","url":"https://clinicaltrials.gov/study/NCT05153447","created_at":"2024-01-09T17:19:21.538Z","updated_at":"2024-07-02T16:35:24.090Z","phase":"","brief_title":"A Multicomponent Technology Supported Care Delivery for Older Patients With Hematologic Malignancies (The M-Tech Study)","source_id_and_acronym":"NCT05153447 - M-Tech","lead_sponsor":"Kah Poh Loh","biomarkers":" IL6 • TNFA • IL2 • IL10 • TNFRSF1A • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • IL10 • TNFRSF1A • IL1B"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-09"},{"id":"f13f9d98-9d60-4ad6-8b7d-183c14dad4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607370","created_at":"2021-01-18T17:44:02.029Z","updated_at":"2024-07-02T16:35:29.959Z","phase":"","brief_title":"Timing for Rectal Surgery After Chemoradiotherapy","source_id_and_acronym":"NCT03607370","lead_sponsor":"National Cancer Institute, Lithuania","biomarkers":" IL6 • IL2RA • IL10 • IL1B","pipe":"","alterations":" ","tags":["IL6 • IL2RA • IL10 • IL1B"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-08"},{"id":"16375f35-57e8-4891-ab8d-34d2a7ad1e54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495894","created_at":"2021-01-18T21:35:34.159Z","updated_at":"2024-07-02T16:35:32.024Z","phase":"Phase 1","brief_title":"Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma","source_id_and_acronym":"NCT04495894","lead_sponsor":"Emory University","biomarkers":" IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-24"}]